This database contains 370 studies, archived under the term: "treatment outcome"
Click here to filter this large number of results.
A multi-center randomized proof-of-concept clinical trial applying ¹⁸FFDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer’s disease
Tzimopoulou, Sofia,
Cunningham, Vincent J.,
Nichols, Thomas E.,
Searle, Graham,
Bird, Nick P.,
Mistry, Prafull,
Dixon, Ian J.,
Hallett, William A.,
Whitcher, Brandon,
Brown, Andrew P.,
Zvartau-Hind, Marina,
Lotay, Narinder,
Lai, Robert Y. K.,
Castiglia, Mary,
Jeter, Barbara,
Matthews, Julian C.,
Chen, Kewei,
Bandy, Dan,
Reiman, Eric M.,
Gold, Michael,
Rabiner, Eugenii A.,
Matthews, Paul M.
Here we report the first multi-center clinical trial in Alzheimer’s disease (AD) using fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months treatment with the PPARγ agonist Rosiglitazone XR versus placebo in 80 mild to moderate AD patients. Secondary objectives included testing for reduction […]
Improved language performance in Alzheimer disease following brain stimulation
Cotelli, Maria,
Calabria, Marco,
Manenti, Rosa,
Rosini, Sandra,
Zanetti, Orazio,
Cappa, Stefano F.,
Miniussi, Carlo
Objectives: Repetitive transcranial magnetic stimulation (rTMS) has been proposed as a possible treatment for the cognitive deficits associated with Alzheimer disease (AD). The aim of this study was to assess the long-term effects, on cognitive performance, of rTMS applied to the left dorsolateral prefrontal cortex (DLPFC) in AD patients.; Methods: Ten AD patients were randomly […]
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M.,
Bell, K. L.,
Galasko, D.,
Galvin, J. E.,
Thomas, R. G.,
van Dyck, C. H.,
Aisen, P. S.
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Keren, R.,
Porsteinsson, A. P.,
van Dyck, C. H.,
Tariot, P. N.,
Gilman, S.,
Arnold, D.,
Abushakra, S.,
Hernandez, C.,
Crans, G.,
Liang, E.,
Quinn, G.,
Bairu, M.,
Pastrak, A.,
Cedarbaum, J. M.
Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).; Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the […]
Effectiveness of nonpharmacological approaches in patients with mild cognitive impairment
Tsolaki, Magda,
Kounti, Fotini,
Agogiatou, Christina,
Poptsi, Eleni,
Bakoglidou, Evangelia,
Zafeiropoulou, Myrto,
Soumbourou, Aikaterini,
Nikolaidou, Evdokia,
Batsila, Georgia,
Siambani, Aikaterini,
Nakou, Stella,
Mouzakidis, Christos,
Tsiakiri, Anna,
Zafeiropoulos, Stavros,
Karagiozi, Konstantina,
Messini, Chaido,
Diamantidou, Alexandra,
Vasiloglou, Maria
Background: Mild cognitive impairment (MCI) patients are at increased risk of developing dementia. There is a conflict if cognitive interventions can improve cognitive and functional performances in order to delay the development of dementia.; Objectives: This study aimed to examine the effectiveness of a holistic cognitive rehabilitation program on patients with MCI.; Methods: The participants, […]
Cognitive training changes hippocampal function in mild cognitive impairment: a pilot study
A randomized pilot experiment examined the neural substrates of response to cognitive training in participants with mild cognitive impairment (MCI). Participants performed exercises previously demonstrated to improve verbal memory and an active control group performed other computer activities. An auditory-verbal fMRI task was conducted before and after the two-month training program. Verbal memory scores improved […]
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S.,
Walsh, S.,
Little, J. T.,
Behan, K.,
Reynolds, B.,
Ward, C.,
Jin, S.,
Thomas, R.,
Aisen, P. S.
Objective: Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD).; Methods: We assessed the safety, tolerability, and efficacy of huperzine A in mild to moderate AD in a multicenter trial in which 210 […]
Donepezil treatment in Alzheimer’s disease patients with and without cerebrovascular lesions: a preliminary report
Na, Hae-Ri,
Kim, SangYun,
Choi, Seong Hye,
Yang, Dong-Won,
Bae, Hee-Joon,
Kim, Jung-Eun,
Park, Mee-Young,
Shim, Yong-Soo,
Kim, Byung-Kun,
Kwon, Jae-Cheol,
Yoo, Bong Goo,
Kim, Byeong-Chae,
Lee, Jung-Seok
Aim: Donepezil has not been evaluated in Korean patients with Alzheimer’s disease (AD) for up to 1 year. The objectives of this study were to evaluate the differential efficacy of donepezil in Korean AD patients with and without concomitant cerebrovascular lesions (CVL).; Methods: This study was a 48-week open-label trial of donepezil in patients with […]
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation
Lott, Ira T.,
Doran, Eric,
Nguyen, Vinh Q.,
Tournay, Anne,
Head, Elizabeth,
Gillen, Daniel L.
Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non-Down syndrome) population. This 2-year randomized, double-blind, placebo-controlled trial assessed […]
Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia
Larsson, Victoria,
Engedal, Knut,
Aarsland, Dag,
Wattmo, Carina,
Minthon, Lennart,
Londos, Elisabet
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias.; Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB) over 24 weeks using caregiver-rated QOL-Alzheimer’s disease (AD) in domains according to the […]